GILD Archives - Page 19 of 29

1 minute read

Gilead Sciences’ Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting

February 3, 1:54 PM

The FDA has approved Gilead Sciences Inc’s (NASDAQ:GILD) Trodelvy (sacituzumab govitecan-hziy) for adult patients with advanced or metastatic breast cancer. The…

GILD

2 minute read

‘Risk Of Overheating’: 4 Experts On Hot January Jobs Report, How The Fed Will React

By Wayne Duggan

February 3, 11:41 AM

The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January.

CLX

1 minute read

SVB Leerink Maintains Market Perform on Gilead Sciences, Raises Price Target to $91

By Benzinga Newsdesk

February 3, 11:04 AM

SVB Leerink analyst David Risinger maintains Gilead Sciences (NASDAQ:GILD) with a Market Perform and raises the price target from $81 to $91.

GILD

1 minute read

Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $112

By Benzinga Newsdesk

February 3, 7:39 AM

Piper Sandler analyst Do Kim maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $111 to $112.

GILD

1 minute read

Why Gilead Sciences Stock Is Trading Higher After Hours

By Adam Eckert

February 2, 6:27 PM

Gilead Sciences Inc (NASDAQ: GILD) shares are trading higher in Thursday's after-hours session after the company reported

GILD

5 minute read

February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More

By Shanthi Rexaline

January 31, 3:33 PM

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.

APLS

1 minute read

Kite and Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-ddBCMA In Multiple Myeloma

By Happy Mohamed

January 30, 10:07 AM

Kite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc. (NASDAQ:ACLX), today announced the closing of the companies' previously announced global strategic collaboration to co-develop and co-commercialize

ACLX

5 minute read

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch

By Shanthi Rexaline

January 29, 6:25 PM

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

AAPL